A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Hangzhou Sciwind Biosciences Co., Ltd. · T2DM · Type 2 Diabetes Mellitus
Phase 3
Completed
623
2025-05
Industry sponsor intelligence
Hangzhou Sciwind Biosciences Co., Ltd.Clinical Pipeline.
Lead-sponsor view of Hangzhou Sciwind Biosciences Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 623
Pipeline overview
Programs by phase and activity.
Velocity
Hangzhou Sciwind Biosciences Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Dulaglutide → | 1 | 0 | 0 | 1 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Hangzhou Sciwind Biosciences Co., Ltd. studies.
This page groups studies where Hangzhou Sciwind Biosciences Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates